Oncology Clinical Trials

Canine Urinary Bladder Cancer

Scottish Terrier Screening Study

This study will begin September 1, 2014. For information, read this article by Dr. Marcia Dawson, Chairman of the Health Trust Fund (Scottish Terrier Club of America).

Click here for an exciting update on our Scottish Terrier Screening Study. Support TCC Bladder Cancer Research with a gift or pledge to the Scottish Terrier Screening Study.

Sue & Frank Severtsen and their Scottish Terrier Pipsqueak presented a generous donation to Dr. Debbie Knapp and the staff of the Purdue Comparative Oncology Program.

Sue & Frank Severtsen and their Scottish Terrier, Pipsqueak, presented a generous donation to Dr. Debbie Knapp and the staff of the Purdue Comparative Oncology Program.

paw in hand

EGR-Directed Toxin

Primary Investigators: Dr. Deborah Knapp

By attaching a toxin to an “epidermal growth factor (“EGF”), it is expected to enter cancer cells more readily via the EGF receptor of TCC and EGFR expression than normal cells and to be better able to kill the cancer cells.  It is instilled directly into the bladder.


  • Confirmed histopathology
  • Measurable disease in the bladder than can be followed to assess antitumor effects
  • Expected survival of 6 weeks or more
  • Normal blood counts
  • Pet owner consent

Compensation:  $100 per month.  All treatments must be done at Purdue.


A new targeted therapy to kill cancer cells that have a specific mutation is expected to be available for dogs in a clinical trial later this year.

paw in hand

Vemurafenib Treatment in Dogs with Bladder Cancer, i.e. Transitional Cell Carcinoma(TCC)

Primary investigator: Dr. Deborah Knapp

Description:  This purpose of this study is to determine the anti-tumor effects, the toxicity (or lack thereof), and the appropriate dose of Vemurafenib in dogs with TCC. Vemurafenib is a drug that kills tumor cells that have a very precise mutation. The goal is to improve the outlook for pet dogs and people with cancer.


  • Biopsy proof of TCC
  • Confirmed BRAF V600E mutation in TCC cells in the urine (a urine test)
  • Measurable cancer lesions that can be followed to assess antitumor effects
  • Acceptable “performance status” (the dogs still feels well)
  • Expected survival ≥ 6  weeks
  • Acceptable kidney function (serum creatinine ≤ 2mg/dl)

Financial incentive: The pet owner is required to pay $250.00 per month for the expenses incurred in the Purdue University Veterinary Teaching Hospital (PUVTH) related to the treatment and monitoring. The funding agency will cover the remainder of the cost related to the vemurafenib treatment and monitoring in the PUVTH. Any work done outside of the PUVTH or any expenses not related to the vemurafenib treatment must be paid by the pet owner.

For more information and to schedule an appointment, please call Ms. Chris Royce, Clinical Trials Coordinator at 765 494-1130 or 765 494-1107, or email roycec@purdue.edu

paw in hand

Study of the Causes and Outcome of TCC in Dogs

Primary Investigators: Dr. Debbie Knapp, Dr. Deepika Dhawan, and collaborators

Description of the Work:

Work is ongoing on several fronts to gain a better understanding of how TCC forms, what makes it respond to therapy or not, and what makes it progress. Veterinarians at Purdue are working diligently in this field, and have also teamed up with multiple scientists on campus and across the country to do molecular analyses to address these critical questions. In order to accomplish this work, it would be extremely helpful to obtain samples of blood, urine, and tumor tissue from dogs with TCC, and to be allowed to perform necropsies on dogs with TCC if they are to be euthanized due to declining quality of life related to the cancer or other conditions. This applies to dogs who are already patients of the Purdue University Veterinary Teaching Hospital and to other dogs that have not yet been to the Teaching Hospital, but which have confirmed or presumptive TCC.

Samples from dogs of any breed are very helpful. In addition to the work being done in dogs of any breed, dogs from breeds that have a higher risk of TCC (Scottish Terriers, West Highland White Terriers, Shetland Sheepdogs, Beagles) are also needed for a collaborative study with Dr. Elaine Ostrander at the National Institutes of Health. Work in these high risk breeds is defining underlying genetic factors that increase TCC risk, and that could lead to strategies to prevent TCC, or to find it earlier and treat it more effectively. Samples from dogs that already have TCC and samples from older dogs in high risk breeds that do not have cancer are needed.

To learn more about the TCC studies or to set up an appointment, please call: Ms. Chris Royce, or Ms. Amalia de Gortari, at (765) 494-1130 or (765) 494-1107. Samples from high risk breed dogs can also be shipped directly to Dr. Ostrander's lab.

paw in hand

Canine Lymphoma

We are currently recruiting dogs with multicentric lymphoma for multiple ongoing clinical studies.

We realize that lymphomas may progress rapidly and that prompt treatment is imperative for optimal patient care. We therefore make every effort to receive patients with a confirmed or tentative diagnosis of lymphoma as quickly as possible. Usually, appointments are available within 24-48 hours' notice.

If you are a veterinarian interested in referring a canine patient with lymphoma for treatment, or if you would like additional information about these studies, please call the VTH at (765) 494-1107 and ask to speak with Ms. Sarah Lahrman, RVT, or Dr. Michael Childress.

paw in hand

Cutaneous Lymphoma

Phase 2 Study of External Beam Radiation Therapy for Dogs with Localized Epitheliotropic Cutaneous T-cell Lymphoma

Primary Investigators: Dr. Michael Childress, Dr. Nicholas Rancilio


Epitheliotropic cutaneous T-cell lymphoma (ETCL) is an uncommon form of skin cancer in dogs.  It is most often treated with the oral chemotherapy drug, lomustine.  However, lomustine rarely controls the cancer for longer than a few months.  Radiation therapy is an effective treatment for humans with ETCL, affording long-term cancer control to 70-80% of patients.  Limited reports also suggest radiation therapy would be highly effective to treat dogs with ETCL.  Unfortunately, the degree of benefit radiation would confer to the average dog with this cancer is impossible to estimate based upon the few published reports of its use.  The purpose of this study is therefore to determine the efficacy of a standardized radiation therapy treatment protocol for dogs with localized ETCL.

Eligibility for Dogs to Participate in the Study:

  • Histopathologically-confirmed epitheliotropic T-cell lymphoma (histopathologic review of biopsy samples at Purdue Animal Disease Diagnostic Laboratory is necessary)
  • Lymphoma confined to one anatomic region treatable within a single radiation field, or two abutting fields.  Dogs with disease spread to regional lymph nodes are eligible.
  • Generally good performance status and absence of serious concurrent illness.

Exclusion Criteria:

  • Lymphomas other than cutaneous T-cell lymphoma
  • Lymphoma spread beyond the regional lymph node to organs such as distant lymph nodes, spleen, liver, or bone marrow
  • Serious concurrent illness including, but not limited to, congestive heart failure, cardiac arrhythmias, life-threatening respiratory illness, or advanced stage liver or kidney disease

Financial Support:

  • Radiation therapy is provided at a discounted rate of $3,000 (normal cost $4,000-4,500)
  • Initial staging tests are provided at a discounted rate of $1,000 (normal cost $1,250)

Trial Start Date: Currently ongoing

For Questions, Please Call: MS. Sarah lahrman, RVT or Dr. Michael Childress at 765-494-1107

paw in hand

Canine Osteosarcoma

Prospective Clinical Trial of Amputation Plus Carboplatin and Piroxicam Chemotherapy for Dogs with Appendicular Skeletal Osteosarcoma

Primary Investigators: Dr. Michael Childress, Dr. Sonia Honkisz


The standard therapy for canine appendicular skeletal osteosarcoma is amputation of the affected leg followed by chemotherapy. However, this therapy is rarely curative, with most dogs living an average of 10-12 months following amputation. Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) with antitumor effects against several cancers. We are investigating whether adding piroxicam to standard carboplatin chemotherapy will improve survival time in dogs with appendicular skeletal osteosarcoma following amputation.

Eligibility for Dogs to Participate in the Study:

  • Histopathologically diagnosed appendicular skeletal osteosarcoma
  • Normal kidney function
  • Suitable candidate for limb amputation, if amputation has not already been performed

Exclusion Criteria:

  • Axial skeletal or extraskeletal osteosarcoma
  • Presence of measurable or radiographically detectable metastatic cancer
  • Renal azotemia
  • Unsuitable candidate for amputation (will be assessed on a patient-to-patient basis)

Financial Support:

  • Laboratory tests related to the study will be discounted by 15%
  • Fees for office visits will be waived

Trial Start Date: Currently ongoing

For Questions, Please Call: Dr. Michael Childress at 765-494-1107

Purdue University College of Veterinary Medicine, 625 Harrison Street, West Lafayette, IN 47907, (765) 494-7607

© 2017 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by PVM Web Communications

If you have trouble accessing this page because of a disability, please contact PVM Web Communications at vetwebteam@purdue.edu.